PTC Therapeutics Inc (NASDAQ: PTCT) is -2.88% lower on its value in year-to-date trading and has touched a low of $23.58 and a high of $54.16 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PTCT stock was last observed hovering at around $43.08 in the last trading session, with the day’s gains setting it 0.76%.
Currently trading at $43.84, the stock is -2.22% and -2.73% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.95 million and changing 1.76% at the moment leaves the stock 19.25% off its SMA200. PTCT registered 56.01% gain for a year compared to 6-month gain of 33.62%. The firm has a 50-day simple moving average (SMA 50) of $45.07 and a 200-day simple moving average (SMA200) of $36.761925.
The stock witnessed a -9.81% loss in the last 1 month and extending the period to 3 months gives it a 19.46%, and is -0.23% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.64% over the week and 4.40% over the month.
PTC Therapeutics Inc (PTCT) has around 995 employees, a market worth around $3.38B and $900.66M in sales. Profit margin for the company is -50.32%. Distance from 52-week low is 85.92% and -19.05% from its 52-week high.
with sales reaching $272.32M over the same period.The EPS is expected to grow by 45.80% this year, but quarterly earnings will post -13.20% year-over-year. Quarterly sales are estimated to shrink -11.31% in year-over-year returns.
PTC Therapeutics Inc (PTCT) Top Institutional Holders
290.0 institutions hold shares in PTC Therapeutics Inc (PTCT), with institutional investors hold 106.25% of the company’s shares. The shares outstanding are 76.95M, and float is at 75.41M with Short Float at 5.57%. Institutions hold 103.58% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 8.97 million shares valued at $274.42 million. The investor’s holdings represent 11.731% of the PTCT Shares outstanding. As of 2024-06-30, the second largest holder is WELLINGTON MANAGEMENT GROUP LLP with 8.21 million shares valued at $251.02 million to account for 10.7307 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 7.77 million shares representing 10.1602% and valued at over $237.67 million, while RTW INVESTMENTS, LP holds 9.6647 of the shares totaling 7.39 million with a market value of $226.08 million.
PTC Therapeutics Inc (PTCT) Insider Activity
The most recent transaction is an insider sale by Utter Christine Marie, the company’s SVP, CHIEF ACCOUNTING OFFICER. SEC filings show that Utter Christine Marie sold 1,662 shares of the company’s common stock on Jan 08 ’25 at a price of $44.50 per share for a total of $73959.0. Following the sale, the insider now owns 64321.0 shares.
PTC Therapeutics Inc disclosed in a document filed with the SEC on Jan 07 ’25 that Utter Christine Marie (SVP, CHIEF ACCOUNTING OFFICER) sold a total of 1,291 shares of the company’s common stock. The trade occurred on Jan 07 ’25 and was made at $45.34 per share for $58534.0. Following the transaction, the insider now directly holds 65983.0 shares of the PTCT stock.
Still, SEC filings show that on Jan 08 ’25, Pauwels Eric (CHIEF EXECUTIVE OFFICER) disposed off 2,136 shares at an average price of $44.50 for $95052.0. The insider now directly holds 86,805 shares of PTC Therapeutics Inc (PTCT).
